11:48 AM EST - Nuvo Research Inc. : announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien, has received a Complete Response Letter from the U.S. Food and Drug Administration following the review of Mallinckrodt's New Drug Application for diclofenac sodium topical solution, 2% w/w. Nuvo Research Inc.
shares T.NRI are trading down $0.02 at $0.06.
